Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

4D Molecular Therapeutics, Inc. - Common Stock (NQ:FDMT)

2.690 -0.200 (-6.92%)
Streaming Delayed Price Updated: 12:17 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 4D Molecular Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
HC Wainwright Creates Bullish Pitch On 4D Molecular Citing 'Broader Systemic Potential'
Via Benzinga
Expert Ratings for 4D Molecular Therapeutics
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022
Upgrades 
Via Benzinga
Cramer On This Stock Down 65% Year-To-Date: 'I Do Believe It's Bottoming, But I Don't Know What Gets It Higher'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said BioXcel Therapeutics Inc (NASDAQ: BTAI) "may be home run or nothing, and that’s always tough." 
Via Benzinga
4D Molecular Shares Fall After Filing For Fabry Disease Trial Amendment
Via Benzinga
Why Foresight Autonomous Shares Jumped 33%; Here Are 83 Biggest Movers From Yesterday
Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares surged 106.3% to close at $0.21 on Wednesday after dipping around 48% on Tuesday. Fast Radius established a timeline for a Chapter 11 sale process. 
Via Benzinga
Why Fast Radius Shares Plunged Around 48%; Here Are 103 Biggest Movers From Yesterday
Gainers Satixfy Communications Ltd. (NYSE: SATX) shares gained 140.7% to settle at $31.80 on Tuesday. 
Via Benzinga
Sea, UiPath, J&J Snack Foods And Other Big Gainers From Tuesday
U.S. stocks closed higher on Tuesday, with the Nasdaq Composite gaining more than 150 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 67 Stocks Moving In Tuesday's Mid-Day Session
Gainers SenesTech, Inc. (NASDAQ: SNES) shares surged 91.7% to $0.2751. SenesTech reported a 1-for-20 reverse stock split. 
Via Benzinga
Dow Surges More Than 300 Points After Producer Prices Increase Less Than Expected
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Azenta (NASDAQ:AZTA) shares rose 32.5% to $61.74 during Tuesday's pre-market session. The company's market cap stands at $4.6 billion. As per the news, the Q4 earnings report came out... 
Via Benzinga
4D Molecular Therapeutics Shares Jump After Early Data From Wet Age-Related Macular Degeneration Trial
Via Benzinga
4D Molecular Therapeutics Announces Interim Clinical Data from On-going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD)
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 56.6% to settle at $19.10 on Friday. 
Via Benzinga
4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-150 for Wet AMD to be Released Monday, November 14, 2022
4D Molecular Therapeutics to host a conference call on November 14th, 8:00 am E.T. 
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4D Molecular Therapeutics Reports Third Quarter 2022 Financial Results
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4D Molecular Therapeutics Announces Interim Clinical Data from Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease at NACFC 2022
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers 
Via Benzinga
4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease to be Presented at NACFC 2022
4D Molecular Therapeutics to host a conference call on November 3rd, 4:30 pm E.T. 
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Kiora Pharma is Starting Human Trials of a Novel Treatment That Could Restore Vision In Patients With Inherited Blindness
Kiora Pharmaceuticals Inc. (NASDAQ: KPRX), a pharmaceutical company specializing in treating eye diseases, is moving its drug candidate KIO-301 into a Phase 1b study in the third quarter of this year. 
Via Benzinga
Why Twin Vee Powercats Is Trading Lower By Over 30%; Here Are 30 Stocks Moving Premarket
Gainers Windtree Therapeutics, Inc (NASDAQ: WINT) rose 50.7% to $0.4827 in pre-market trading after the company said Istaroxime Phase 2 study in early cardiogenic shock was published in the European... 
Via Benzinga
4D Molecular Therapeutics Appoints Noriyuki Kasahara, MD, PhD to the Board of Directors and Promotes Fred Kamal, PhD to President and Chief Operating Officer
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2022
Upgrades 
Via Benzinga
Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday
Gainers Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results. 
Via Benzinga
Why Twin Vee Powercats Is Trading Higher By Around 90%, Here Are 84 Stocks Moving In Friday's Mid-Day Session
Gainers Twin Vee Powercats Co. (NASDAQ: VEEE) shares jumped 90% to $7.60 after the company said Q2 sales results were up year over year. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2022
  
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
91 Biggest Movers From Friday
Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 123 stocks made new 52-week lows. 
Via Benzinga
Looking Into 4D Molecular Therapeutics's Return On Capital Employed
Benzinga Pro data, 4D Molecular Therapeutics (NASDAQ:FDMT) reported Q4 sales of $92.00 thousand. Earnings fell to a loss of $25.08 million, resulting in a 12.79% decrease from last quarter. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS